Lenvatinib-induced psoriasiform eruption and palmoplantar erythema in a patient with hepatocellular carcinoma

Rachel Sally, BA, Nkemjika Ugonabo, MD, MPH, Andy Nguyen, MD, Randie H. Kim, MD, PhD, and Kristen Lo Sicco, MD
New York, New York

Key words: drug eruption; hepatocellular carcinoma; lenvatinib; psoriasiform drug eruption; psoriasis; tyrosine kinase inhibitors.

INTRODUCTION

Lenvatinib is an oral multiple tyrosine receptor kinase inhibitor currently approved by the US Food and Drug Administration for the treatment of thyroid cancer, renal cell carcinoma, hepatocellular carcinoma (HCC), and endometrial carcinoma.1 Its mechanism of action is selective inhibition of vascular endothelial growth factor receptors (VEGFRs) 1 to 3, fibroblast growth factor receptors 1 to 4, RET, KIT, and platelet-derived growth factor receptor-α. Cutaneous adverse events are common among antiangiogenic treatments and include psoriasiform eruptions, which have been observed with other VEGFR inhibitors.2,3 Here, we report, to our knowledge, a novel case of psoriasiform drug eruption following lenvatinib therapy.

CASE REPORT

A 66-year-old Chinese man with a history of chronic hepatitis type B, liver cirrhosis, HCC, and end-stage renal disease on hemodialysis presented to our dermatology clinic with a 6-week history of a progressive, pruritic eruption on his upper and lower extremities, trunk, abdomen, hands, and feet, in addition to a desquamative, tender palmoplantar eruption. Both eruptions began 2 weeks after initiating lenvatinib therapy at the dosage of 12 mg orally once daily for progressive and metastatic HCC. He had previously received other liver-directed therapy, including radiofrequency ablation, transcatheter arterial chemoembolization, radioembolization with yttrium-90, stereotactic body radiotherapy, nivolumab (which was discontinued due to disease progression), and microwave ablation.

On physical examination, the patient had numerous well-demarcated, pruritic, scaly plaques on the upper and lower extremities, trunk, abdomen, hands, and feet, in addition to a desquamative, tender palmoplantar eruption. Both eruptions began 2 weeks after initiating lenvatinib therapy at the dosage of 12 mg orally once daily for progressive and metastatic HCC. He had previously received other liver-directed therapy, including radiofrequency ablation, transcatheter arterial chemoembolization, radioembolization with yttrium-90, stereotactic body radiotherapy, nivolumab (which was discontinued due to disease progression), and microwave ablation.

On physical examination, the patient had numerous well-demarcated, pruritic, scaly plaques on the upper and lower extremities, trunk, abdomen, hands, and feet, in addition to a desquamative, tender palmoplantar eruption. Both eruptions began 2 weeks after initiating lenvatinib therapy at the dosage of 12 mg orally once daily for progressive and metastatic HCC. He had previously received other liver-directed therapy, including radiofrequency ablation, transcatheter arterial chemoembolization, radioembolization with yttrium-90, stereotactic body radiotherapy, nivolumab (which was discontinued due to disease progression), and microwave ablation.

Due to the progression of his oncologic disease, lenvatinib was later discontinued in favor of cabozantinib.

Abbreviations used:

- HCC: hepatocellular carcinoma
- MKI: multikinase inhibitor
- VEGF: vascular endothelial growth factor
- VEGFR: vascular endothelial growth factor receptor

From the Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine.
Author Sally and Dr Ugonabo are cofirst authors.
Funding sources: None.
IRB approval status: Not applicable.
Correspondence to: Kristen Lo Sicco, MD, Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, 240 East 38th Street, 11th Floor, New York, NY 10016. E-mail: Kristen.LoSicco@nyulangone.org.
DISCUSSION

The vascular endothelial growth factor (VEGF) signaling pathway is a key regulator of tumor vasculature, mediating endothelial cell proliferation, migration, vascular permeability, and vasodilation. Lenvatinib and sorafenib are closely related multi-kinase inhibitors (MKIs) that inhibit VEGFR. However, lenvatinib differs from other MKIs, particularly sorafenib, in its ability to inhibit fibroblast growth factor receptor signaling, which is associated with the activation of cellular cascades and responses such as cell growth, proliferation, differentiation, apoptosis, and survival.

Currently, lenvatinib is approved by the US Food and Drug Administration for the treatment of advanced endometrial carcinoma, unresectable HCC, advanced renal cell carcinoma, and differentiated thyroid cancer. Although dermatologic adverse events, including palmar-plantar dysesthesia, hair and skin discoloration, and xerosis, are commonly seen with lenvatinib and other MKIs, to our knowledge, no reports on psoriasiform drug eruption associated with lenvatinib exist. Adverse events related to lenvatinib typically occur early in the course of therapy within the first 2 months of initiation. In this case, the psoriasiform eruption and cooccurring palmar-plantar dysesthesia emerged after 6 weeks of lenvatinib therapy, suggesting a temporal link. Furthermore, the patient had no prior history of psoriasis or psoriasiform-like rashes prior to the lenvatinib therapy.

The pathogenesis of more common cutaneous toxicities, such as acral erythema, of VEGFR inhibitors is suggested to be due to epidermal cell apoptosis or interactions between endothelial cells and stroma; however, the literature remains inconclusive to date. In psoriasis pathogenesis, VEGF has been implicated as it is overexpressed on psoriatic keratinocytes, contributes to epidermal hyperplasia, and induces angiogenesis. Therefore, it seems paradoxical that psoriasiform eruptions have been observed following sorafenib and, now, lenvatinib therapy, given that both block VEGFR signaling. Furthermore, reports that describe the treatment with sorafenib and sunitinib, both related MKIs, exist, leading to the remission of existing psoriasis. Current hypotheses regarding the pathogenesis of sorafenib-induced psoriasiform reactions involve the hypoxia-inducible factor pathway, which is upstream of VEGF. Sorafenib upregulates HIF-2α, which has been found to be upregulated in psoriatic plaques. Currently, there are sparse data in the literature regarding the specific effect of lenvatinib on the hypoxia-inducible factor pathways and circulating VEGF. Lenvatinib has more immunomodulatory effects than sorafenib and has been shown to increase the proportion of T lymphocytes compared with controls. Psoriasis is largely T lymphocyte-mediated, so an upregulation of T cells is a possible mechanism by which lenvatinib causes psoriasiform dermatitides. The underlying biologic mechanisms by which VEGFR inhibitors such as lenvatinib induce or exacerbate psoriasis remain unclear and may differ between MKIs due to
the variability in their targets and affinities and discrete immunomodulatory effects.

In conclusion, cutaneous toxicities are frequently reported side effects of MKIs. Although reactions such as the psoriasiform drug eruption described in this case are not life-threatening, they are impactful on patients’ quality of life as well as the continuation of the oncologic medication. With the increasing use of targeted therapies such as lenvatinib, dermatologists will play an important role in the early recognition and management of adverse cutaneous reactions. Early assessment of skin-related toxicities is critical to mitigate the reaction without compromising treatment of the malignancy.

Conflicts of interest
None disclosed.

REFERENCES
1. Hao Z, Wang P. Lenvatinib in management of solid tumors. Oncologist. 2020;25(2):e302-e310.
2. Cubero DIG, Abdalla BMZ, Schoueri J, et al. Cutaneous side effects of molecularly targeted therapies for the treatment of solid tumors. Drugs Context. 2018;7:212516.
3. Ensslin CJ, Kao PH, Wu MY, et al. Psoriasiform drug eruption secondary to sorafenib: case series and review of the literature. Cutis. 2019;104(3):E11-E15.
4. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8(8):579-591.
5. Casadei Gardini A, Puzzoni M, Montagnani F, et al. Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all phase III trials. Onco Targets Ther. 2019;12:2981-2988.
6. Haddad RI, Schlumberger M, Wirth LJ, et al. Incidence and timing of common adverse events in lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine. 2017;56(1):121-128.
7. van Kester MS, Luelmo SAC, Vermeer MH, Blank C, van Doorn R. Remission of psoriasis during treatment with sorafenib. JAAD Case Rep. 2018;4(10):1065-1067.
8. Narayanan S, Agarwal N, Callis-Duffin K, Batten J. Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. Am J Med Sci. 2010;339(6):580-581.
9. Yiu ZZ, Ali FR, Griffiths CE. Paradoxical exacerbation of chronic plaque psoriasis by sorafenib. Clin Exp Dermatol. 2016;41(4):407-409.
10. Kimura T, Kato Y, Ozawa Y, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci. 2018;109(12):3993-4002.